PDL BioPharma Price to Free Cash Flow Ratio 2006-2020 | PDLI

Historical price to free cash flow ratio values for PDL BioPharma (PDLI) since 2006. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
PDL BioPharma Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2020-12-30 2.47 0.00
2020-12-31 2.47 $-0.16 0.00
2020-06-30 2.91 $-0.76 0.00
2020-03-31 2.82 $-0.39 0.00
2019-12-31 3.25 $-0.28 0.00
2019-09-30 2.16 $-0.13 0.00
2019-06-30 3.14 $0.21 14.85
2019-03-31 3.72 $-0.04 0.00
2018-12-31 2.90 $-0.12 0.00
2018-09-30 2.63 $-0.23 0.00
2018-06-30 2.34 $-0.30 0.00
2018-03-31 2.94 $-0.17 0.00
2017-12-31 2.74 $0.25 10.89
2017-09-30 3.39 $0.47 7.23
2017-06-30 2.47 $0.43 5.73
2017-03-31 2.27 $0.38 5.99
2016-12-31 2.12 $0.62 3.42
2016-09-30 3.35 $0.95 3.51
2016-06-30 3.14 $1.48 2.12
2016-03-31 3.28 $1.99 1.65
2015-12-31 3.44 $1.84 1.86
2015-09-30 4.69 $1.76 2.66
2015-06-30 5.82 $1.81 3.22
2015-03-31 6.23 $1.70 3.67
2014-12-31 6.68 $1.69 3.96
2014-09-30 6.36 $1.68 3.78
2014-06-30 8.11 $1.45 5.60
2014-03-31 6.85 $1.75 3.91
2013-12-31 6.84 $1.69 4.04
2013-09-30 6.35 $1.74 3.65
2013-06-30 6.04 $1.66 3.64
2013-03-31 5.60 $1.68 3.34
2012-12-31 5.29 $1.45 3.65
2012-09-30 5.68 $1.27 4.47
2012-06-30 4.79 $1.35 3.55
2012-03-31 4.49 $1.15 3.89
2011-12-31 4.27 $0.96 4.47
2011-09-30 3.73 $0.88 4.24
2011-06-30 3.85 $0.79 4.87
2011-03-31 3.71 $0.82 4.55
2010-12-31 3.88 $1.03 3.77
2010-09-30 3.28 $1.12 2.92
2010-06-30 3.20 $1.12 2.87
2010-03-31 3.54 $1.00 3.54
2009-12-31 3.64 $1.01 3.59
2009-09-30 3.34 $2.15 1.55
2009-06-30 3.17 $2.52 1.26
2009-03-31 2.84 $0.26 10.87
2008-12-31 2.31 $3.49 0.66
2008-09-30 2.51 $2.42 1.04
2008-06-30 2.86 $1.59 1.80
2008-03-31 1.99 $3.55 0.56
2007-12-31 3.28 $-0.06 0.00
2007-09-30 4.05 $-0.41 0.00
2007-06-30 4.37 $0.07 58.32
2007-03-31 4.07 $0.21 18.94
2006-12-31 3.78 $0.37 10.16
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00